Prevalence, Burden, and Diagnosis in AD
Allies in the Race Against Time: Navigating AD with Early Detection, Therapeutic Innovations, and Patient-Centric Care
Chuck Vega, MD
University of California Irvine
James Galvin, MD, MPH
Professor of Neurology
Chief, Division of Cognitive Neurology
Director, Comprehensive Center for Brain Health Director, Lewy Body Dementia Research Center of Excellence
Upon completion of this activity, the participant should be able to:
- Recognize the significance of early recognition and diagnosis of Alzheimer's Disease (AD) in improving patient outcomes and quality of life
- Explain how to apply knowledge of validated and emerging biomarkers in the early diagnosis of AD to enhance patient-specific treatment decisions
Physician Accreditation Statement
Physician Credit Designation
Instructions to Receive Credit
- Read the learning objectives and faculty disclosures Complete the pretest
- View the enduring material
- Complete the posttest with a score of 70% or higher
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.
Fee Information and Refund/Cancellation Policy
Disclosures of Relevant Financial Relationships
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
James Galvin, MD MPH
Consulting Fee (e.g., Advisory Board): Biogen, Cognivue, Eisai, Eli Lilly, GE Healthcare, Genentech, Roche
Stock Option Holder: Cognivue
Ian Kremer has no relevant financial relationships with ineligible companies to disclose.
The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This educational activity is supported by independent educational grants from Eisai, Inc.